Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
BMO Wealth Management's Carol Schleif breaks down inflation, Fed policy, earnings, AI investment, and where investors may find opportunities in today's market.
Fast Company's Christopher Zara breaks down the OpenAI-Apple legal battle, the AI chip race, and what's next for the future of artificial intelligence.
Glacier CEO Rebecca Hu-Thrams explains how AI-powered robots are making recycling smarter, reducing landfill waste, and transforming the future of waste.
Deep Fission CEO Liz Muller discusses underground nuclear reactors, powering AI, cutting energy costs, and why the future of clean power may be below ground.
Adidas shares how FIFA World Cup 2026 will drive innovation, fan engagement, and billions in opportunity with new gear, technology, and business strategy.
Kristian Kerr, Head of Macro Strategy at LPL Financial, breaks down the firm's 2026 Mid-Year Outlook, recession risks, AI, the Fed, and what's next for markets.
